Ablative Therapy in the Management of Prostate Cancer
About This Trial
- This study is observing how well targeted treatments—which destroy only the cancerous spots in the prostate using methods like heat, cold, or sound waves—work for patients over time.
- It is open to adults whose prostate cancer has not spread to other parts of the body, and who are either planning to have or have already received one of these targeted therapies.
- Because this is an observational study, researchers will not assign or change your treatment; instead, they will simply track your health outcomes and ask you to complete questionnaires in English about your recovery.
More Information
- The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This study is observing how well targeted treatments—which destroy only the cancerous spots in the prostate using methods like heat, cold, or sound waves—work for patients over time.
Study Details
- Start Date: January 2, 2018
- Lead Sponsor: Weill Medical College of Cornell University
Full Eligibility Criteria
Inclusion Criteria
- >18 years of age
- Undergoing focal therapy for primary or salvage treatment of prostate cancer, or
- Have received prior focal therapy
Exclusion Criteria
- Clinically-evident metastatic disease
- Unable to fill out an English-language questionnaire
Treatments
- Device: cryotherapy